ANI Pharmaceuticals, Inc. — Earnings Quality Grade F
ANIP · Healthcare
Major red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 116 days, change -16 days YoY
AR growth 26.8% vs revenue growth 43.8%
Revenue 43.8%, CFFO 189.3%. Cash follows revenue
Expense Quality
Inventory 4.6% vs COGS 36.4%. Normal
CapEx growth 102.4% is >2x revenue growth 43.8%
SG&A/Gross Profit = 58.6%. Normal
Gross margin 61.4%, change +2.1pp. Stable
Cash Flow Quality
CFFO/NI = 2.36. Profits backed by cash
FCF $0.2B, FCF/NI = 1.93
Accruals ratio = -7.4%. Low accruals
Cash $0.3B covers only 48% of debt $0.6B
Balance Sheet Health
Goodwill+Intangibles $0.5B = 100% of equity. Over 50%
Debt/EBITDA = 3.0x. Healthy
Insufficient data
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -10% YoY. Normal
Manipulation Score
M-Score = -2.62 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25